BSX VS REGN Stock Comparison
Performance
BSX100/100
100/100
BSX returned 26.68% in the last 12 months. Based on SPY's performance of -12.97%, its performance is above average giving it a score of 100 of 100.
REGN23/100
23/100
REGN returned 10.99% in the last 12 months. Based on SPY's performance of 15.09%, its performance is below average giving it a score of 22 of 100.
Analyst Price Targets
BSX79/100
79/100
24 analysts offer 12-month price targets for BSX. Together, they have an average target of 57.93, the most optimistic target put BSX at 132 within 12-months and the most pessimistic has BSX at 43.
REGN68/100
68/100
26 analysts offer 12-month price targets for REGN. Together, they have an average target of 791.45, the most optimistic target put REGN at 976 within 12-months and the most pessimistic has REGN at 604.
Technicals
BSX89/100
89/100
BSX receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.
REGN86/100
86/100
REGN receives a 85 of 100 based on 14 indicators. 11 are bullish, 1 are bearish.
Earnings
BSX26/100
26/100
BSX has missed earnings 4 times in the last 20 quarters.
REGN100/100
100/100
REGN has missed earnings 1 times in the last 20 quarters.
Profit
BSX72/100
72/100
Out of the last 20 quarters, BSX has had 18 profitable quarters and has increased their profits year over year on 8 of them.
REGN80/100
80/100
Out of the last 20 quarters, REGN has had 20 profitable quarters and has increased their profits year over year on 9 of them.
Volatility
BSX48/100
48/100
BSX has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
REGN57/100
57/100
REGN has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.
Dividend
BSX10/100
10/100
BSX's most recent dividend was $0.01 per share, based on a share price of $53.85. It was a payout ratio of -8.24% compared to their total earnings.
REGN
"Dividend" not found for REGN
Sentiment
BSX
"Sentiment" not found for BSX
REGN72/100
72/100
REGN had a bullish sentiment score of 72.04% across Twitter and StockTwits over the last 12 months. It had an average of 38.16 posts, 65.65 comments, and 370.30 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
Boston Scientific Corp. Summary
New York Stock Exchange / BSX
Healthcare
Medical - Devices
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Regeneron Pharmaceuticals Inc Summary
Nasdaq / REGN
Healthcare
Biotechnology
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare BSX to other companies in the same or a similar industry.